Eli Lilly opens a new legal front in its battle against compounded GLP-1s
Eli Lilly sued four telehealth firms, but it is adopting a new legal strategy in its fight against compounded GLP-1s.
Related Articles
Akeso wins Chinese approval for cancer drug positioned to rival Merck’s Keytruda
An Akeso lung cancer drug that beat Merck’s Keytruda in a head-to-head trial won approval in China this week
Up and down the ladder: The latest comings and goings
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
Luigi Mangione pleads not guilty to federal death penalty charge in UnitedHealthcare CEO’s killing
Luigi Mangione pleaded not guilty Friday to a federal murder charge in the killing of UnitedHealthcare CEO Brian Thompson as prosecutors formally declared their intent to seek…
Rural health study is told it’s losing federal funds, and other major heart studies are worried
A federal health study that was examining the high burden of chronic disease in rural areas learned its funding has been cut off.
Sutter Health will pay nearly $230 million to settle class-action antitrust case
Sutter Health has agreed to pay about $230 million to settle a federal class-action lawsuit accusing it of anticompetitive behavior
Day by day, how Trump is roiling science and health
STAT is tracking, day by day, what’s happened in the words of science and health during the first months of the Trump administration.
NIH announces six new acting institute directors, many of them filling posts of ousted predecessors
The NIH announced six acting directors to run institutes, many to fill vacancies created by the ouster of predecessors
Vanderbilt medical center warns suppliers not to raise prices due to tariffs, or they may not get paid
Amid growing anxiety over tariffs, one medical center has warned its suppliers that any sudden price hikes attributed to the levies may be rejected.
With the FDA in turmoil, the ‘revolving door’ with industry is spinning faster
HHS Robert F. Kennedy Jr. has railed against a “revolving door” between drug companies and the FDA. But HHS’ actions now seem to be causing…
Trump’s first 100 days, seen through 5 lives: Grants terminated. Dreams crushed. Futures in the balance
STAT spoke with people living through the historic disruptions threatening the future of biomedical research in the U.S. These are their stories